14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $84.70 $93.35 Monday, 22nd Apr 2024 BMRN stock ended at $89.49. This is 0.97% more than the trading day before Friday, 19th Apr 2024. During the day the stock fluctuated 1.03% from a day low at $88.89 to a day high of $89.81.
90 days $83.44 $94.51
52 weeks $76.02 $99.55

Historical BioMarin Pharmaceutical Inc. prices

Date Open High Low Close Volume
Feb 08, 2024 $89.77 $90.18 $87.47 $88.15 1 076 292
Feb 07, 2024 $89.46 $91.06 $88.50 $89.66 2 218 452
Feb 06, 2024 $88.12 $90.05 $87.58 $89.80 1 483 967
Feb 05, 2024 $87.76 $88.33 $87.08 $87.72 1 121 406
Feb 02, 2024 $87.91 $88.43 $87.29 $88.11 837 377
Feb 01, 2024 $87.72 $88.87 $87.26 $88.74 1 186 819
Jan 31, 2024 $89.67 $90.01 $87.64 $88.08 1 061 324
Jan 30, 2024 $91.59 $91.59 $89.43 $89.62 1 369 752
Jan 29, 2024 $91.00 $91.78 $89.47 $91.78 675 330
Jan 26, 2024 $91.62 $91.65 $90.37 $90.87 1 093 164
Jan 25, 2024 $92.51 $92.92 $90.70 $91.25 1 188 532
Jan 24, 2024 $93.30 $93.82 $92.11 $92.31 1 123 079
Jan 23, 2024 $94.51 $94.51 $92.44 $93.04 1 759 958
Jan 22, 2024 $92.00 $94.22 $91.52 $94.04 1 231 156
Jan 19, 2024 $92.69 $92.93 $91.85 $92.25 1 086 685
Jan 18, 2024 $93.53 $93.81 $92.08 $92.53 815 407
Jan 17, 2024 $92.99 $93.88 $92.10 $93.43 715 215
Jan 16, 2024 $92.97 $94.06 $92.08 $93.46 1 044 670
Jan 12, 2024 $95.51 $96.55 $92.96 $93.33 1 730 669
Jan 11, 2024 $95.13 $96.65 $94.59 $96.00 1 919 111
Jan 10, 2024 $96.38 $96.95 $95.05 $95.89 911 184
Jan 09, 2024 $98.19 $98.19 $95.17 $96.13 1 110 466
Jan 08, 2024 $96.21 $99.25 $94.92 $99.00 959 395
Jan 05, 2024 $96.64 $97.08 $95.81 $96.47 670 826
Jan 04, 2024 $96.67 $98.44 $96.50 $97.73 1 027 655
Click to get the best stock tips daily for free!

About BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical. BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form o... BMRN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT